Navigation Links
HPS Establishes Independent Website for its Patent-Pending Mood-Enhancing Compound Naturally Found in Sea Coral

SAN JOSE, Calif., Jan. 21 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the Company") announced that it has established a website devoted to its newly-announced mood- enhancing compound, ER 303, for which the Company filed Comprehensive Patent Applications with both the U.S. Patent and Trademark Office and the International Bureau of the World Patent Office. On the site, the Company released additional data regarding the testing that was performed on male and female volunteers, which show significant improvement in several aspects of mood enhancement.

"We felt it appropriate to develop this website to respond to requests received about this innovative and previously undeveloped compound, with its origin in sea coral, which has significant emotional impacts on both men and women, enhancing feelings of positive social relationships, personal well- being and social attraction", a Company spokesperson noted. "Hopefully, the data contained on this site will answer initial questions that have been posed since the Company's original announcement", the spokesperson indicated.

In addition to the Company's earlier disclosure, the data included on details the definitive results of the testing that was performed, and confirms that prior to the Company's reproduction of this naturally-occurring compound, it could only be found in coral reefs off the coasts of Newfoundland and in the waters off Brazil's Guiabinha Island.

The Company has previously been granted broad-based worldwide patents for its initial compound, Androstadienone, which has been licensed to leading marketers, including Johnson & Johnson, Avon and Schwarkopf and Henkel and its affiliates.

This news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10- KSB for the year ended December 31, 2007, and Form 10-Q for the nine months ended September 30, 2008 as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.

SOURCE Human Pheromone Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Daiichi Sankyo, Inc. Establishes Subsidiary in Puerto Rico
2. Cystic Fibrosis Foundation Establishes Landmark Patient Assistance Foundation
3. Body-Jet Water-Assisted Liposuction Establishes New Standard for Liposuction and Fat Harvesting
4. Johnson & Johnson Establishes Wellness & Prevention Platform with Acquisition of HealthMedia, Inc.
5. Halleland Health Consulting Establishes URAC Accreditation Program
6. Jenny Craig Establishes License Agreement for Volumetrics(R)
7. Disabled Veteran Establishes Non-Profit, AVHRT, to House Injured Veterans
8. Sonic Innovations Establishes Donation Fund for the Armed Forces Foundation
9. Leading Performance-Enhancing Drug Research Institute Anti-Doping Research (ADR) Establishes Nonprofit Status
10. AmeriCares Establishes Field Hospital in China
11. InterComponentWare Establishes ICW Labs
Post Your Comments:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology: